Xconomy: Biogen Idec Rebuts Icahn Attack, GlaxoSmithKline Quietly Spins Off Tempero Pharmaceuticals, Knome Launches Cheaper Sequencing Service, & More Boston-Area Life Sciences News
Summary
—Cambridge, MA-based Molecular Insight Pharmaceuticals (NASDAQ:MIPI) named a new president and CEO, Daniel Peters, just months after giving that post to co-founder John Babich.Babich will stay on as chief scientific officer of Molecular, which is developing a cardiac imaging agent called Zemiva.—Ryan chatted with Jeff Carbeck, co-founder of Watertown, MA-based Arsenal Medical, chief scientist at Cambridge, MA-based Nano-Terra, and newly named New England Clean Energy Council fellow.One of the top chemical engineers to come out of the lab of Harvard’s George Whitesides, Carbeck is bringing material science discoveries to bear not only in medical products but also in clean technology and a host of other industries.—Biogen Idec (NASDAQ: BIIB) launched a one-two punch at Carl Icahn, the billionaire investor campaigning to take over the board of the Cambridge, MA-based biotech giant.